| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $871,774 ) |
| | 2024 | 2024 | TENDEL THERAPIES INC. | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R44AI179586 | GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine | 001 | 2 | NIH | 5/29/2024 | $571,691 |
| | 2024 | 2024 | TENDEL THERAPIES INC. | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R43MH133246 | Genetic adjuvants to elicit neutralizing antibodies against HIV | 000 | 2 | NIH | 1/17/2024 | $300,083 |
| | 2024 | 2023 | TENDEL THERAPIES INC. | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R44AI179586 | GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine | 000 | 1 | NIH | 10/25/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,600,930 ) |
| | 2023 | 2023 | TENDEL THERAPIES INC | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R43MH133246 | Genetic adjuvants to elicit neutralizing antibodies against HIV | 000 | 1 | NIH | 2/6/2023 | $300,930 |
| | 2023 | 2023 | TENDEL THERAPIES INC | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R41AI165350 | CCR5 immunotoxins as components of HIV cure regimens | 000 | 2 | NIH | 6/16/2023 | $300,000 |
| | 2023 | 2023 | TENDEL THERAPIES INC | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R44AI179586 | GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine | 000 | 1 | NIH | 7/11/2023 | $1,000,000 |
| | 2023 | 2023 | TENDEL THERAPIES INC | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R43MH133246 | Genetic adjuvants to elicit neutralizing antibodies against HIV | 001 | 1 | NIH | 6/7/2023 | $0 |
| | 2023 | 2021 | TENDEL THERAPIES INC. | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R41AI157626 | Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2 | 000 | 1 | NIH | 9/12/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $300,000 ) |
| | 2022 | 2022 | TENDEL THERAPIES INC. | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R41AI165350 | CCR5 immunotoxins as components of HIV cure regimens | 000 | 1 | NIH | 7/13/2022 | $300,000 |
| | 2022 | 2020 | TENDEL THERAPIES INC | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R41AI150232 | Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines | 000 | 1 | NIH | 5/20/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $299,983 ) |
| | 2021 | 2021 | TENDEL THERAPIES INC. | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R41AI157626 | Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2 | 000 | 1 | NIH | 12/30/2020 | $299,983 |
|
| Issue Date FY: 2020 ( Subtotal = $300,000 ) |
| | 2020 | 2020 | TENDEL THERAPIES INC. | 420 YALE AVE | KENSINGTON | CA | 94708-1109 | ALAMEDA | USA | R41AI150232 | Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines | 000 | 1 | NIH | 4/6/2020 | $300,000 |
|
|
